In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

Carbon monoxide can be deadly. Every year, over 400 people in the U.S. die unintentionally from CO poisoning, and more than 100,000 wind up in emergency rooms, according to the Centers for Disease ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

In the end, the efficacy of a radar detector boils down to a delicate interplay of technology, law enforcement tactics, and a driver's skill and awareness. While it can provide a valuable edge in ...

I’ve been writing about consumer technology and video games for more than a decade at a variety of publications, including Destructoid, GamesRadar+, Lifewire, PCGamesN, Trusted Reviews, and What Hi-Fi ...